Ellacor Micro-Coring for Wound Care

Recruiting at 1 trial location

Overseen By Delia Medical Science Liaison, PharmD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Cytrellis Biosystems, Inc.

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

24 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Since its inception of being marketed in the United States in 2021, physicians have used various post procedure skin care regimen to facilitate recovery. This study aims to examine the use of three post care products in five skin care regimens

Are You a Good Fit for This Trial?

This trial is for individuals who have undergone skin treatments using Ellacor Micro-Coring Technology. Participants should be following specific post-procedural care regimens, but the exact eligibility criteria are not provided in the given information.

Inclusion Criteria

Willingness to sign Informed Consent Form

Fitzpatrick Skin Type I to IV

Have moderate to severe wrinkles on the mid and lower face, according to Lemperle Wrinkle Severity Scale (LWSS), i.e. score 3, 4 or 5

Exclusion Criteria

I have not had facial plastic surgery or scars less than 12 months old.

I have not had injections or skin treatments in the area for the last 6 months.

I am not willing to avoid cosmetic treatments during the study.

What Are the Treatments Tested in This Trial?

Interventions

• Ellacor® Micro-coring®

Trial Overview The study investigates the safety and effectiveness of different post-care products used in five distinct skin care routines after treatment with Ellacor Micro-Coring Technology, which has been available in the U.S. since 2021.

How Is the Trial Designed?

Group I: Regenerating Skin Nectar (by Alastin) + Tegaderm Active Control 1 Intervention

Alastin to be applied post procedure followed up Tegaderm. Tegaderm will be left on for 12 hours. Alastin will be applied twice daily for the duration of the study

Group II: Ariessence PDGF solution + Kerra+ Recovery Cream + Tegaderm Active Control 1 Intervention

Patients will receive PDGF immediately post procedure followed by Kerra+ followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Kerra+ will continue to be applied twice daily for the duration of the study

Group III: Tegaderm Only Active Control 1 Intervention

Patient will only receive Tegaderm for post-care

Group IV: Kerra+ Recovery Cream (by Quthero) + Tegaderm Active Control 1 Intervention

Patients will receive Kerra+ post procedure followed by Tegaderm. The Tegaderm is removed after 12 hours. Kerra+ will be applied twice daily for the duration of the study.

Group V: Ariessence Platelet-Derived Growth Factor (PDGF) solution +Alastin + Tegaderm Active Control 1 Intervention

Patients will receive PDGF immediately post procedure followed by Alastin followed by Tegaderm. The Tegaderm will be removed after 12 hours and the Alastin will continue to be applied twice daily for the duration of the study

Who Is Running the Clinical Trial?

Cytrellis Biosystems, Inc.

Lead Sponsor

Trials

7

Recruited

180+